Children's Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Phase 3

Active, not recruiting

Conditions: Extraocular Retinoblastoma

Interventions: Procedure: Autologous Bone Marrow Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Biological: Filgrastim
Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Radiation: Radiation Therapy
Drug: Thiotepa
Drug: Vincristine Sulfate

First Posted Date: 2007-11-07

Last Posted Date: 2024-10-22

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 60

Registration Number: NCT00554788

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 70 locations

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: anti-thymocyte globulin
Drug: busulfan
Drug: cyclophosphamide
Drug: cyclosporine
Drug: methotrexate
Drug: methylprednisolone
Drug: tacrolimus
Other: laboratory biomarker analysis
Other: pharmacological study
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation

First Posted Date: 2007-11-04

Last Posted Date: 2020-04-16

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 158

Registration Number: NCT00553202

Locations: 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

and more 49 locations

Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

Not Applicable

Completed

Conditions: Adult Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: Asparaginase
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2007-09-28

Last Posted Date: 2019-07-09

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 59

Registration Number: NCT00537030

Locations: 🇺🇸
Harbor-University of California at Los Angeles Medical Center, Torrance, California, United States
🇺🇸
Kalamazoo Center for Medical Studies, Kalamazoo, Michigan, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 40 locations

Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

Interventions: Drug: carboplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: topotecan hydrochloride
Procedure: Surgery
Drug: Isotretinoin
Drug: Filgrastim

First Posted Date: 2007-07-11

Last Posted Date: 2021-07-06

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 464

Registration Number: NCT00499616

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

and more 186 locations

Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed

Conditions: Untreated Childhood Acute Lymphoblastic Leukemia
Untreated Adult Acute Lymphoblastic Leukemia

Interventions: Other: laboratory biomarker analysis

First Posted Date: 2007-06-05

Last Posted Date: 2023-08-03

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 11196

Registration Number: NCT00482352

Locations: 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of Illinois, Chicago, Illinois, United States

and more 197 locations

Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: cytarabine
Drug: idarubicin
Drug: lestaurtinib

First Posted Date: 2007-05-07

Last Posted Date: 2017-03-15

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 14

Registration Number: NCT00469859

Locations: 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 18 locations

Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: cytarabine

First Posted Date: 2007-05-07

Last Posted Date: 2014-10-20

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 10

Registration Number: NCT00470275

Locations: 🇺🇸
Columbus Children's Hospital, Columbus, Ohio, United States
🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
Tulane Cancer Center Office of Clinical Research, Alexandria, Louisiana, United States

and more 70 locations

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Phase 2

Completed

Conditions: Childhood Extracranial Germ Cell Tumor
Childhood Malignant Ovarian Germ Cell Tumor
Childhood Malignant Testicular Germ Cell Tumor
Ovarian Yolk Sac Tumor
Recurrent Childhood Malignant Germ Cell Tumor
Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
Ovarian Embryonal Carcinoma
Recurrent Malignant Testicular Germ Cell Tumor
Ovarian Choriocarcinoma
Recurrent Ovarian Germ Cell Tumor

Interventions: Drug: Carboplatin
Biological: Filgrastim
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel

First Posted Date: 2007-04-27

Last Posted Date: 2018-08-29

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 20

Registration Number: NCT00467051

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Palmetto Health Richland, Columbia, South Carolina, United States

and more 92 locations

Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment

Phase 1

Withdrawn

Conditions: Brain and Central Nervous System Tumors
Unspecified Childhood Solid Tumor, Protocol Specific
Leukemia
Lymphoma

First Posted Date: 2007-04-11

Last Posted Date: 2014-08-08

Lead Sponsor: Children's Oncology Group

Registration Number: NCT00458744

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Completed

Conditions: Ototoxicity
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Procedure: management of therapy complications

First Posted Date: 2007-04-11

Last Posted Date: 2017-03-13

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 301

Registration Number: NCT00458887

Locations: 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States

and more 78 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy